Pyrimethamine Market Synopsis:
Pyrimethamine Market Size Was Valued at USD 1.20 Billion in 2023, and is Projected to Reach USD 1.94 Billion by 2032, Growing at a CAGR of 5.5% From 2024-2032.
Pyrimethamine is an antimalarial and antibacterial drug in the 2, 4-diaminopyrimidines class widely used together with other drugs to treat toxoplasmosis and, in some cases, pellagra Daraprim is the brand name of pyrimethamine. Global Shingles Market defines pyrimethamine in the current market as it forms and makes up this market.The pyrimethanine market represents the production, sales and usage of pyrimethamine – the antifol, folic acid antagonist, which can be used in protozoal diseases including malaria and toxoplasmosis. This market is emerging on account of these factors including incidence of these diseases, development in formulation delivery systems and growing awareness of the existing treatment among the afflicted regions.
The market is in a state of constant development because this preparation is used for the treatment of malaria and toxoplasmosis which are diseases that occur worldwide. Tropical and subtropical diseases such as malaria are still a challenge to the health care systems of the world today. Co-deborders of pyrimethamine are normally used and pyrimethamine is very important in controlling resistant strains of malaria. Besides, its use in treating toxoplasmosis in immunocompromised patients has also fuel the market even further.
This demonstrate that as public policies and international programs aimed at launching an effort to lower the rates of malaria affect demand for powerful antimalarial agents like pyrimethamine. As has the sector’s attention to the need to provide this drug in such markets as the low and middle-income countries at an affordable price. However, certain factors such as higher drug resistance and other regulation issues of price and drugs in market could slow down the market.
Pyrimethamine Market Trend Analysis:
Rise of Combination Therapies
- As stated above, the supply of pyrimethamine has also been limited to a number of countries whose patient populace is graduallyique accepting combination therapies. The drug is often given together with other drugs such as sulfadoxine in malaria or sulfadiazine in toxoplasmosis. Together with treatment, combinations allow not only improving the outcome of the treatment but also eliminates the risk of drug resistance, a rather critical issue in the treatment of infections. A number of pharmaceutical businesses are investing huge amount towards developing new combined drugs to have a greater patient value which in turn is addressing global efforts for containing resistance.
Expansion in Emerging Markets
- The pyrimethamine through product sale in emerging markets offer a vast prospect in the market. Malaria endemic countries, particularly those in Africa, South East Asia and some parts of South America are shifting to the use of pyrimethamine containing antimalarial treatments because of the effectiveness of the treatment. There are a lot of global forums and government health programmes that are being aimed at raising the stock of cheap antimalarial drugs in these areas. Furthermore, with the growing awareness level in conjunction with an improvement in the healthcare facility in these zones would help fuel the growth of the market throughout the forecast period.
Pyrimethamine Market Segment Analysis:
The Pyrimethamine Market is Segmented on the basis of Dosage Form, Indication, Distribution Channel, and Region
By Dosage Form, Tablets segment is expected to dominate the market during the forecast period
- In the course of the forecast period, the Tablets segment is expected to dominate the pyrimethamine market. The tablets are the most preferred dosage form for the?s in this study since they are easy to administer, convenient and cheap. This segment has been continuing to grow because; it is used cross different developed and developing regions for treatment of malaria and toxoplasmosis. New innovative formulations like sustained release tablet & combination tablets are also exerting benefits to the patients’ compliance and therapeutic effects which add to the buoyancy of the tablet segment.
By Indication, the Malaria segment is expected to held the largest share
- The market of pyrimethamine is expected to be dominated by the Malaria segment. Due to the fact that malaria is still a universal menace especially to many African nations the call for effective treatment modalities is felt all the time. This makes the pyrimethamine as an essential part of antimalarial regimens owing to its efficacy against strains of malaria parasite. The increased use of pyrimethamine in malaria treatments has been contributed by malaria control and elimination programs funded by different governments and non-governmental organizations.
Pyrimethamine Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America will be the largest consumer of pyrimethamine during the forecast period owing to increased health care amenities, superior knowledge of the diseases infecting humans and an active pharmaceutical research center. Early detection of toxoplasmosis and increasing preference for the immuno compromised population set high intensity of medical treatments of toxoplasmosis is a notable factor that has greatly expanded the market. But due to market availability of broad suppliers of pyrimethamine in United States and Canada then the market is well sorted for good quality of pyrimethamine drugs and products.
- The North America market adopted the legal framework to advance its prospect, strict rules affirm the efficiency of the drugs. High pet density increases the usage of pyrimethamine in treating toxoplasmosis prevalent in cats, which act as carriers of the disease. On the same regard, string clinical research and programs focusing on fighting drug resistance are thought to support the region as the leading market.
Active Key Players in the Pyrimethamine Market:
- Actavis Pharma (United States)
- Alvogen (United States)
- Bayer AG (Germany)
- Cipla Limited (India)
- GlaxoSmithKline plc (United Kingdom)
- Hikma Pharmaceuticals (United Kingdom)
- Lupin Pharmaceuticals, Inc. (India)
- Mylan N.V. (United States)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Ranbaxy Laboratories (India)
- Roche Holding AG (Switzerland)
- Sanofi S.A. (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries (Israel)
- Other Active Players
|
Pyrimethamine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.20 Billion |
|
Forecast Period 2024-32 CAGR: |
5.5% |
Market Size in 2032: |
USD 1.94 Billion |
|
Segments Covered: |
By Dosage Form |
|
|
|
By Indication |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Pyrimethamine Market by By Dosage Form (2018-2032)
4.1 Pyrimethamine Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Tablets
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Capsules
Chapter 5: Pyrimethamine Market by By Indication (2018-2032)
5.1 Pyrimethamine Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Malaria
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Toxoplasmosis
5.5 Others
Chapter 6: Pyrimethamine Market by By Distribution Channel (2018-2032)
6.1 Pyrimethamine Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Retail Pharmacies
6.5 Online Pharmacies
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Pyrimethamine Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ACULAB (UNITED KINGDOM)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 AGNITIO SL (SPAIN)
7.4 AURAYA SYSTEMS (AUSTRALIA)
7.5 BIOMETRIC VOX (SPAIN)
7.6 CISCO SYSTEMS INC. (UNITED STATES)
7.7 DAON INC. (UNITED STATES)
7.8 ID R&D (UNITED STATES)
7.9 INTERSEC GROUP (FRANCE)
7.10 LUMENVOX LLC (UNITED STATES)
7.11 NUANCE COMMUNICATIONS INC. (UNITED STATES)
7.12 PHONEXIA (CZECH REPUBLIC)
7.13 SESTEK (TURKEY)
7.14 SENSORY INC. (UNITED STATES)
7.15 VALIDSOFT UK LTD. (UNITED KINGDOM)
7.16 VOICEPIN.COM (POLAND)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Pyrimethamine Market By Region
8.1 Overview
8.2. North America Pyrimethamine Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By By Dosage Form
8.2.4.1 Tablets
8.2.4.2 Capsules
8.2.5 Historic and Forecasted Market Size By By Indication
8.2.5.1 Malaria
8.2.5.2 Toxoplasmosis
8.2.5.3 Others
8.2.6 Historic and Forecasted Market Size By By Distribution Channel
8.2.6.1 Hospital Pharmacies
8.2.6.2 Retail Pharmacies
8.2.6.3 Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Pyrimethamine Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By By Dosage Form
8.3.4.1 Tablets
8.3.4.2 Capsules
8.3.5 Historic and Forecasted Market Size By By Indication
8.3.5.1 Malaria
8.3.5.2 Toxoplasmosis
8.3.5.3 Others
8.3.6 Historic and Forecasted Market Size By By Distribution Channel
8.3.6.1 Hospital Pharmacies
8.3.6.2 Retail Pharmacies
8.3.6.3 Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Pyrimethamine Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By By Dosage Form
8.4.4.1 Tablets
8.4.4.2 Capsules
8.4.5 Historic and Forecasted Market Size By By Indication
8.4.5.1 Malaria
8.4.5.2 Toxoplasmosis
8.4.5.3 Others
8.4.6 Historic and Forecasted Market Size By By Distribution Channel
8.4.6.1 Hospital Pharmacies
8.4.6.2 Retail Pharmacies
8.4.6.3 Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Pyrimethamine Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By By Dosage Form
8.5.4.1 Tablets
8.5.4.2 Capsules
8.5.5 Historic and Forecasted Market Size By By Indication
8.5.5.1 Malaria
8.5.5.2 Toxoplasmosis
8.5.5.3 Others
8.5.6 Historic and Forecasted Market Size By By Distribution Channel
8.5.6.1 Hospital Pharmacies
8.5.6.2 Retail Pharmacies
8.5.6.3 Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Pyrimethamine Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By By Dosage Form
8.6.4.1 Tablets
8.6.4.2 Capsules
8.6.5 Historic and Forecasted Market Size By By Indication
8.6.5.1 Malaria
8.6.5.2 Toxoplasmosis
8.6.5.3 Others
8.6.6 Historic and Forecasted Market Size By By Distribution Channel
8.6.6.1 Hospital Pharmacies
8.6.6.2 Retail Pharmacies
8.6.6.3 Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Pyrimethamine Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By By Dosage Form
8.7.4.1 Tablets
8.7.4.2 Capsules
8.7.5 Historic and Forecasted Market Size By By Indication
8.7.5.1 Malaria
8.7.5.2 Toxoplasmosis
8.7.5.3 Others
8.7.6 Historic and Forecasted Market Size By By Distribution Channel
8.7.6.1 Hospital Pharmacies
8.7.6.2 Retail Pharmacies
8.7.6.3 Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Pyrimethamine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 1.20 Billion |
|
Forecast Period 2024-32 CAGR: |
5.5% |
Market Size in 2032: |
USD 1.94 Billion |
|
Segments Covered: |
By Dosage Form |
|
|
|
By Indication |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Pyrimethamine Market research report is 2024-2032.
Actavis Pharma (United States), Alvogen (United States), Bayer AG (Germany), Cipla Limited (India), GlaxoSmithKline plc (United Kingdom), Hikma Pharmaceuticals (United Kingdom), Lupin Pharmaceuticals, Inc. (India), Mylan N.V. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Ranbaxy Laboratories (India), Roche Holding AG (Switzerland), Sanofi S.A. (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), and Other Active Players
The Pyrimethamine Market is segmented into Dosage Form, Indication, Distribution Channel, and Region. By Dosage Form, the market is categorized into Tablets and Capsules. By Indication, the market is categorized into Malaria Toxoplasmosis and Others. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By Region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Pyrimethamine is an antimalarial and antibacterial drug in the 2, 4-diaminopyrimidines class widely used together with other drugs to treat toxoplasmosis and, in some cases, pellagra Daraprim is the brand name of pyrimethamine. Global Shingles Market defines pyrimethamine in the current market as it forms and makes up this market. The pyrimethanine market represents the production, sales and usage of pyrimethamine – the antifol, folic acid antagonist, which can be used in protozoal diseases including malaria and toxoplasmosis. This market is emerging on account of these factors including incidence of these diseases, development in formulation delivery systems and growing awareness of the existing treatment among the afflicted regions.
Pyrimethamine Market Size Was Valued at USD 1.20 Billion in 2023, and is Projected to Reach USD 1.94 Billion by 2032, Growing at a CAGR of 5.5% From 2024-2032.
